Theresa E. Matson

Theresa E. Matson

Auto-generated profile, based on publicly available information

Theresa E. Matson

Kaiser Permanente Washington Health Research Institute, Seattle, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
TMTheresa E. Matson
Theresa E. Matson
GLGwen T. Lapham
Gwen T. Lapham
JBJennifer F. Bobb
Jennifer F. Bobb
MOMalia Oliver
Malia Oliver
KHKevin A. Hallgren
Kevin A. Hallgren
KBKatharine A. Bradley
Katharine A. Bradley
Importance: Cannabis use is prevalent and increasing, and frequent use intensifies the risk of cannabis use disorder (CUD). CUD is underrecognized in medical settings, but a validated single-item cannabis screen could increase recognition.Objective: To evaluate the Single-Item Screen–Cannabis (SIS-C), administered and documented in routine primary care, compared with a confidential reference standard measure of CUD.Design, Setting, and Participants: This diagnostic study included a sample of adult patients who completed routine cannabis screening between January 28 and September 12, 2019, and were randomly selected for a confidential survey about cannabis use. Random sampling was stratified by frequency of past-year use and race and ethnicity. The study was conducted at an integrated health system in Washington state, where adult cannabis use is legal. Data were analyzed from May 2021 to March 2022.Exposures: The SIS-C asks about frequency of past-year cannabis use with responses (none, less than monthly, monthly, weekly, daily or almost daily) documented in patients’ medical records.Main Outcomes and Measures: The Diagnostic and Statistical Manual, Fifth Edition (DSM-5) Composite International Diagnostic Interview–Substance Abuse Module (CIDI-SAM) for past-year CUD was completed on a confidential survey and considered the reference standard. The SIS-C was compared with 2 or more criteria on the CIDI-SAM, consistent with CUD. All analyses were weighted, accounting for survey design and nonresponse, to obtain estimates representative of the health system primary care population.Results: Of 5000 sampled adult patients, 1688 responded to the cannabis survey (34% response rate). Patients were predominantly middle-aged (weighted mean [SD] age, 50.7 [18.1]), female or women (weighted proportion [SE], 55.9% [4.1]), non-Hispanic (weighted proportion [SE], 96.7% [1.0]), and White (weighted proportion [SE], 74.2% [3.7]). Approximately 6.6% of patients met criteria for past-year CUD. The SIS-C had an area under receiver operating characteristic curve of 0.89 (95% CI, 0.78-0.96) for identifying CUD. A threshold of less than monthly cannabis use balanced sensitivity (0.88) and specificity (0.83) for detecting CUD. In populations with a 6% prevalence of CUD, predictive values of a positive screen ranged from 17% to 34%, while predictive values of a negative screen ranged from 97% to 100%.Conclusions and Relevance: In this diagnostic study, the SIS-C had excellent performance characteristics in routine care as a screen for CUD. While high negative predictive values suggest that the SIS-C accurately identifies patients without CUD, low positive predictive values indicate a need for further diagnostic assessment following positive results when screening for CUD in primary care.

23 December 2023 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
CSClaire B. Simon
Claire B. Simon
CMConnor J. McCabe
Connor J. McCabe
TMTheresa E. Matson
Theresa E. Matson
MOMalia Oliver
Malia Oliver
KBKatharine A. Bradley
Katharine A. Bradley
KHKevin A. Hallgren
Kevin A. Hallgren

7 June 2018 in BMC Public Health
Verified
Journal Article
Open access
PDF file
TMTheresa E. Matson
Theresa E. Matson
ARAnne D. Renz
Anne D. Renz
MTMichelle L. Takemoto
Michelle L. Takemoto
JMJennifer B. McClure
Jennifer B. McClure
DRDori Rosenberg
Dori Rosenberg
Older adults spend more time sitting than any other age group, contributing to poor health outcomes. Effective behavioral interventions are needed to encourage less sitting among older adults, specifically those with obesity, but these programs must be acceptable to the target population. We explored participant acceptance of a theory-based and technology-enhanced sitting reduction intervention designed for older adults (I-STAND). The 12-week I-STAND intervention consisted of 6 health coaching contacts, a study workbook, a Jawbone UP band to remind participants to take breaks from sitting, and feedback on sitting behaviors (generated from wearing an activPAL device for 7 days at the beginning and mid-point of the study). Semi-structured interviews were conducted with 22 participants after they completed the intervention. Interview transcripts were iteratively coded by a team, and thematic analysis was used to identify and refine emerging themes. Overall, participants were satisfied with the I-STAND intervention, thought the sedentary behavior goals of the intervention were easy to incorporate, and found the technologies to be helpful additions to (but not substitutes for) health coaching. Barriers to standing more included poor health, ingrained sedentary habits, lack of motivation to change sedentary behavior, and social norms that dictate when it is appropriate to sit/stand. Facilitators to standing more included increased awareness of sitting, a sense of accountability, daily activities that involved standing, social support, and changing ways of interacting in the home environment. Participants reported that the intervention improved physical health, increased energy, increased readiness to engage in physical activity, improved mood, and reduced stress. The technology-enhanced sedentary behavior reduction intervention was acceptable, easy to incorporate, and had a positive perceived health impact on older adults with obesity. The I-STAND study was registered at clinicaltrials.gov (ID: NCT02692560 ) February 2016.

3 May 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
TMTheresa E. Matson
Theresa E. Matson
DCDavid S. Carrell
David S. Carrell
JBJennifer F. Bobb
Jennifer F. Bobb
DCDavid J. Cronkite
David J. Cronkite
MOMalia M. Oliver
Malia M. Oliver
GLGwen T. Lapham
Gwen T. Lapham
Medical and recreational cannabis use is increasing in the US.1,2 Most US states have legal access to cannabis,3,4 and the perceived risk of cannabis use is decreasing.1,5 Many people may use cannabis to manage medical and psychiatric symptoms and sometimes to replace prescribed medications despite little understanding of the potential risks and benefits of cannabis.6 Cannabis use is thus highly relevant to a patient’s medical care, but how often it is addressed in health care settings with medical practitioners is unknown. Electronic health record (EHR) data can provide novel information on how often medical cannabis use is recognized and documented during outpatient encounters.

11 March 2022 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
KHKevin A. Hallgren
Kevin A. Hallgren
TMTheresa E. Matson
Theresa E. Matson
MOMalia Oliver
Malia Oliver
RCRyan M. Caldeiro
Ryan M. Caldeiro
DKDaniel R. Kivlahan
Daniel R. Kivlahan
KBKatharine A. Bradley
Katharine A. Bradley

1 May 2023 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
TMTheresa E. Matson
Theresa E. Matson
KHKevin A. Hallgren
Kevin A. Hallgren
GLGwen T. Lapham
Gwen T. Lapham
MOMalia Oliver
Malia Oliver
XWXiaoming Wang
Xiaoming Wang
KBKatharine A. Bradley
Katharine A. Bradley
Importance: Substance use disorders (SUDs) are underrecognized in primary care, where structured clinical interviews are often infeasible. A brief, standardized substance use symptom checklist could help clinicians assess SUD.Objective: To evaluate the psychometric properties of the Substance Use Symptom Checklist (hereafter symptom checklist) used in primary care among patients reporting daily cannabis use and/or other drug use as part of population-based screening and assessment.Design, Setting, and Participants: This cross-sectional study was conducted among adult primary care patients who completed the symptom checklist during routine care between March 1, 2015, and March 1, 2020, at an integrated health care system. Data analysis was conducted from June 1, 2021, to May 1, 2022.Main Outcomes and Measures: The symptom checklist included 11 items corresponding to SUD criteria in the Diagnostic and Statistical Manual for Mental Disorders (Fifth Edition) (DSM-5). Item response theory (IRT) analyses tested whether the symptom checklist was unidimensional and reflected a continuum of SUD severity and evaluated item characteristics (discrimination and severity). Differential item functioning analyses examined whether the symptom checklist performed similarly across age, sex, race, and ethnicity. Analyses were stratified by cannabis and/or other drug use.Results: A total of 23 304 screens were included (mean [SD] age, 38.2 [5.6] years; 12 554 [53.9%] male patients; 17 439 [78.8%] White patients; 20 393 [87.5%] non-Hispanic patients). Overall, 16 140 patients reported daily cannabis use only, 4791 patients reported other drug use only, and 2373 patients reported both daily cannabis and other drug use. Among patients with daily cannabis use only, other drug use only, or both daily cannabis and other drug use, 4242 (26.3%), 1446 (30.2%), and 1229 (51.8%), respectively, endorsed 2 or more items on the symptom checklist, consistent with DSM-5 SUD. For all cannabis and drug subsamples, IRT models supported the unidimensionality of the symptom checklist, and all items discriminated between higher and lower levels of SUD severity. Differential item functioning was observed for some items across sociodemographic subgroups but did not result in meaningful change (<1 point difference) in the overall score (0-11).Conclusions and Relevance: In this cross-sectional study, a symptom checklist, administered to primary care patients who reported daily cannabis and/or other drug use during routine screening, discriminated SUD severity as expected and performed well across subgroups. Findings support the clinical utility of the symptom checklist for standardized and more complete SUD symptom assessment to help clinicians make diagnostic and treatment decisions in primary care.